The
US FDA has granted its tentative approval to Aurobindo
Pharma Ltd''s Stavudine Oral solution 1mg / ml.
The
product will now be available under the ''US President''s
emergency plan for AIDS relief'' (PEPFAR). Following
this approval, the total number of Aurobindo Pharma
ARV products for the PEPFAR programme has gone up to
nine.
Stavudine
Oral solution 1mg / ml is the first generic version
approval of Zerit for oral solutions manufactured by
Bristol-Myers Squibb. This child-friendly product is
indicated for use in paediatric patients with HIV, from
birth through adolescence.
Stavudine
is active against the human immunodeficiency virus (HIV)
that causes AIDS. It is in the class of drugs called
nucleoside reverse transcriptase inhibitors (NRTIs),
which help keep the AIDS virus
from reproducing. This anti-retroviral drug is used
in combination with other anti-retroviral agents for
the treatment of HIV-1 infection.
|